 The LNCaP prostate cancer cell line expresses AR with a T877A point mutation that causes proliferation in the presence of the antiandrogens hydroxyflutamide and cyproterone acetate.This mutation has also been discovered in patients with antiandrogen withdrawal syndrome being treated with these compounds.In another study, bicalutamide treatment of LNCaP cells resulted in two LBD mutations, W741L and W741C, causing bicalutamide to acquire agonist activity to both mutant ARs.